[The role of blood-brain barrier in the pathogenesis of Alzheimer dementia--implications for immunological therapies for plaque dissolution]

Fortschr Neurol Psychiatr. 2009 Aug:77 Suppl 1:S21-4. doi: 10.1055/s-0028-1109601. Epub 2009 Aug 14.
[Article in German]


Alzheimer's disease (AD) is a devastating neurodegenerative disorder affecting more than 27 million people worldwide and leading to severe social-economic problems. One characteristic hallmark of AD--the amyloid plaques--are still being discussed to be one important triggering factor. However, current animal and autopsy studies refer to soluble and highly toxic A block oligomers as the deadly agent for the neurons. Current therapies mainly rely on the abatement of symptoms without antagonizing the etiology of the disease. Potential new approaches address reduced production, increased degradation and/or evacuation of toxic A block peptides from the brain. Among others one important group of target-proteins are the ABC transporters of the blood-brain barrier which contribute importantly to the detoxification of the brain. Changes of specific transport functions evoke important alterations for the known pathogenesis and future therapies of AD, especially approaches that target plaque dissolution and plaque reduction.

MeSH terms

  • ATP-Binding Cassette Transporters / metabolism
  • Alzheimer Disease / immunology
  • Alzheimer Disease / pathology*
  • Alzheimer Disease / therapy*
  • Amyloid beta-Peptides / metabolism
  • Blood-Brain Barrier / drug effects
  • Blood-Brain Barrier / physiology*
  • Humans
  • Immunotherapy*
  • Neurons / pathology
  • Plaque, Amyloid / immunology
  • Plaque, Amyloid / pathology*


  • ATP-Binding Cassette Transporters
  • Amyloid beta-Peptides